Calliditas Therapeutics AB (NAS:CALT)
$ 40.0001 -0.1599 (-0.4%) Market Cap: 1.08 Bil Enterprise Value: 1.10 Bil PE Ratio: 0 PB Ratio: 104.30 GF Score: 35/100

Calliditas Therapeutics AB KOL Webinar Transcript

Nov 08, 2022 / 06:30PM GMT
Release Date Price: $14.31 (-3.29%)
Operator

Good afternoon, and welcome to the Calliditas Therapeutics fireside chat. (Operator Instructions) As a reminder, this call is being recorded, and a replay will be made available on the Calliditas website following the conclusion of the event. I'd now like to turn the call over to Renee Lucander, Chief Executive Officer of Calliditas Therapeutics. Please go ahead, Renee.

Renee Aguiar;Lucander;publ;CEO
Calliditas Therapeutics AB

()-

Thank you. Welcome, everybody, and thank you for joining this presentation by Dr. Richard Lafayette on the treatment landscape of IgA nephropathy and recently published data in this space.

So Dr. Lafayette is a Professor of Medicine on Nephrology at the Stanford University Medical Center. He has, as many of you know, a very impressive background in the area nephrology and a long-standing interest in glomera diseases with a focus on IgA nephropathy. He's a Founder and Director of the Stanford Glomerular Disease Center and its fellowship training program. He has over 25 years of

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot